Application note: Middle-up mass analysis of protease digested cetuximab
Posted: 30 November 2022 | Merck | No comments yet
Protocol for purification, proteolysis, reduction and UHPLC-MS analysis of unlabelled and labelled monoclonal antibodies
This application note details a complete workflow of a middle-up mass analysis of protease digested Cetuximab monoclonal antibody, starting with the antibody purification, proteolysis and reduction to its reversed phase UHPLC-MS analysis.
Related content from this organisation
- MSD set to acquire novel antibody for B-cell malignancies
- Novel immunotherapy combination approved for endometrial cancer
- Innovating small molecule injectables: market forecast to 2033
- Ophthalmology acquisition to advance tri-specific antibody
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
